Atacor Medical
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
131 Calle Iglesia Ste 120, San Clemente,...Phone Number
(949) 482-1038Website
www.atacor.comRevenue
$10 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Atacor Medical
Established in 2014, AtaCor Medical is transforming cardiac pacing. AtaCor's extracardiac pacing lead is being designed to be inserted without any need for medical imaging, allowing for faster, less-invasive therapy delivery. The unique placement avoids the need to access the patient's vascular system and leaves the heart completely untouched. Furthermore, the extracardiac lead is designed to eliminate bedrest restrictions associated with temporary pacing, thereby improving patient mobility and post-procedural recovery. AtaCor's management team is comprised of seasoned experts from within the implantable cardiac device and electrophysiology fields, with over 80 years of combined experience. The company's extracardiac pacing system is being developed for temporary and permanent pacing markets and is not yet approved for sale in any geography.Explore more
Atacor Medical Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Atacor Medical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Atacor Medical recently announced quarterly report
Funding: Get notified immidiatlly once Atacor Medical has new funding data
Check out if Atacor Medical is spiking on competitors!
Click to see if Atacor Medical had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Atacor Medical
Check if Atacor Medical has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Atacor Medical, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Atacor Medical launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Atacor Medical
Compare insights from companies similar to Atacor Medical, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Atacor Medical is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Atacor Medical is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Atacor Medical.
Atacor Medical financials insights
Gather financial insights about Atacor Medical, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Series A
$8.8M
2020
Series B
$25M
2024
Series C
$28M
2025
Other Financing Round
$75M
Atacor Medical Tech Stack
A closer look at the technologies used by Atacor Medical
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Product Development, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Funding
Funding
Atacor Medical News & Media
AtaCor Medical Secures $75M Financing to Support the Pivotal U.S. Study of its Extravascular ICD (EV-ICD) System
The novel design of AtaCor's Atala™ lead aims to provide reliable sensing, antitachycardia pacing (ATP), and shock therapies with no hardware placed in the heart or vasculature SAN CLEMENTE, Calif., Oct. 6, 2025 /PRNewswire/ -- AtaCor Medical, Inc., a privately-held medical device company...AtaCor Medical Enrolls First Patients in its ASCEND EV Clinical Study
The novel design of AtaCor's EV-ICD Atala™ lead aims to provide reliable sensing, antitachycardia pacing (ATP), and shock therapies through an extravascular approach Initial cases demonstrated successful sensing and defibrillation of induced ventricular fibrillation with the Atala™ lead,...ATACOR MEDICAL CLOSES $28M SERIES C FINANCING TO DELIVER NEXT GENERATION EXTRAVASCULAR ICD AND PACING OPTIONS FOR CARDIAC RHYTHM MANAGEMENT
Funding Supports Regulatory Submissions and Clinical Milestones for Proprietary Extravascular (EV) Pacing & Implantable Cardioverter Defibrillator (ICD) Lead Systems SAN CLEMENTE, Calif., April 24, 2024 /PRNewswire/ -- AtaCor Medical Inc., a privately-held medical device company...AtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--AtaCor Medical, Inc. has announced completion of its second human clinical study of the Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System. Building on acute data from the PASS PULL EV-ICD Study (n=18) completed in Q1-2022, the Sensing and Defibrillation with a Commercially Available ICD coupled with a Parasternal Extravascular Lead (SECURE EV) study (n=18) followed subjects with an AtaCor Medical EV-ICD lead connected to a commercia
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Atacor Medical
Sign Up For FreeTo access detailed company insights
Established in 2014, AtaCor Medical is transforming cardiac pacing. AtaCor's extracardiac pacing lead is being designed to be inserted without any need for medical imaging, allowing for faster, less-invasive therapy delivery. The unique placement avoids the need to access the patient's vascular system and leaves the heart completely untouched. Furt... Read More
